Accelerating HIV-1 Vaccine Efficacy Trials.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 25416935.
- Also identified by DOI 10.1016/j.cell.2014.10.046 and PMC identifier 4246198.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic. Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outline strategies to accelerate efficacy evaluation of novel HIV-1 vaccine candidates.
Medical subject headings
- AIDS Vaccines
- Clinical Trials as Topic
- HIV-1